TAOX

SEC source: 0001104659-22-128770 · tm2233089-5_4seq1.xml · nonDerivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,238

F1 · shares: Shares sold pursuant to a Rule 10b5-1 sales plan, entered into on December 6, 2021 and amended and restated on October 24, 2022, to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

SEC source: 0001104659-22-128772 · tm2233089-7_4seq1.xml · nonDerivative · entry 1

Singer William S. · CIK 0001617927 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,000

F1 · shares: Shares sold pursuant to a Rule 10b5-1 sales plan, entered into on December 6, 2021 and amended and restated on October 24, 2022, to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

SEC source: 0001104659-22-128769 · tm2233089-4_4seq1.xml · nonDerivative · entry 1

SCHECHTER JONATHAN · CIK 0001619259 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,500

F1 · shares: Shares sold pursuant to a Rule 10b5-1 sales plan, entered into on December 6, 2021 and amended and restated on October 24, 2022, to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

SEC source: 0001104659-22-128766 · tm2233089-2_4seq1.xml · nonDerivative · entry 1

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,578

F1 · shares: Shares sold pursuant to a Rule 10b5-1 sales plan, entered into on December 6, 2021 and amended and restated on October 24, 2022, to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

SEC source: 0001104659-22-119879 · tm2230820-4_4seq1.xml · derivative · entry 1

Alkon Daniel L. · CIK 0001686138 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,000

Underlying: Common Stock, par value $0.0001 per share · 112,000 shares

Expires 2032-11-15

F1 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer.

SEC source: 0001104659-22-119876 · tm2230820-2_4seq1.xml · derivative · entry 1

TUCHMAN ALAN J · CIK 0001417631 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,000

Underlying: Common Stock, par value $0.0001 per share · 112,000 shares

Expires 2032-11-15

F1 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer.

SEC source: 0001104659-22-119880 · tm2230820-5_4seq1.xml · derivative · entry 1

WEINSTEIN ROBERT · CIK 0001213709 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,000

Underlying: Common Stock, par value $0.0001 per share · 96,000 shares

Expires 2032-11-15

F1 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer.

SEC source: 0001104659-22-119881 · tm2230820-6_4seq1.xml · derivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,000

Underlying: Common Stock, par value $0.0001 per share · 144,000 shares

Expires 2032-11-15

F1 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer.

SEC source: 0001104659-22-119882 · tm2230820-7_4seq1.xml · derivative · entry 1

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock, par value $0.0001 per share · 80,000 shares

Expires 2032-11-15

F1 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer.

SEC source: 0001104659-22-119877 · tm2230820-3_4seq1.xml · derivative · entry 1

Singer William S. · CIK 0001617927 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,000

Underlying: Common Stock, par value $0.0001 per share · 96,000 shares

Expires 2032-11-15

F1 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer.

SEC source: 0001104659-22-119873 · tm2230820-1_4seq1.xml · derivative · entry 1

SCHECHTER JONATHAN · CIK 0001619259 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,000

Underlying: Common Stock, par value $0.0001 per share · 72,000 shares

Expires 2032-11-15

F1 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer.

SEC source: 0001104659-22-123800 · tm2231816-3_4aseq1.xml · derivative · entry 1

Alkon Daniel L. · CIK 0001686138 · Director · See Remark

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock, par value $0.0001 per share · 75,000 shares

Expires 2032-11-15

F1 · shares: This filing amends the Form 4, filed on November 17, 2022 by Mr. Alkon to reflect the lower number of options allowed to be granted pursuant to the per-participant grant limit contained in the Issuer's 2020 Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer.

SEC source: 0001104659-22-123798 · tm2231816-1_4aseq1.xml · derivative · entry 1

TUCHMAN ALAN J · CIK 0001417631 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,850

Underlying: Common Stock, par value $0.0001 per share · 68,850 shares

Expires 2032-11-15

F1 · shares: This filing amends the Form 4, filed on November 17, 2022 by Mr. Tuchman to reflect the lower number of options allowed to be granted pursuant to the per-participant grant limit contained in the Issuer's 2020 Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer.

SEC source: 0001104659-22-123808 · tm2231816-8_4aseq1.xml · derivative · entry 1

WEINSTEIN ROBERT · CIK 0001213709 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock, par value $0.0001 per share · 75,000 shares

Expires 2032-11-15

F1 · shares: This filing amends the Form 4, filed on November 17, 2022 by Mr. Weinstein to reflect the lower number of options allowed to be granted pursuant to the per-participant grant limit contained in the Issuer's 2020 Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer.

SEC source: 0001104659-22-123802 · tm2231816-4_4aseq1.xml · derivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock, par value $0.0001 per share · 75,000 shares

Expires 2032-11-15

F1 · shares: This filing amends the Form 4, filed on November 17, 2022 by Mr. Silverman to reflect the lower number of options allowed to be granted pursuant to the per-participant grant limit contained in the Issuer's 2020 Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer.

SEC source: 0001104659-22-123803 · tm2231816-5_4aseq1.xml · derivative · entry 1

Singer William S. · CIK 0001617927 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock, par value $0.0001 per share · 75,000 shares

Expires 2032-11-15

F1 · shares: This filing amends the Form 4, filed on November 17, 2022 by Mr. Singer to reflect the lower number of options allowed to be granted pursuant to the per-participant grant limit contained in the Issuer's 2020 Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer.

SEC source: 0001104659-22-123799 · tm2231816-2_4aseq1.xml · derivative · entry 1

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock, par value $0.0001 per share · 75,000 shares

Expires 2032-11-15

F1 · shares: This filing amends the Form 4, filed on November 17, 2022 by Mr. Bernstein to reflect the lower number of options allowed to be granted pursuant to the per-participant grant limit contained in the Issuer's 2020 Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer.

SEC source: 0001104659-22-043275 · tm2212026-3_4seq1.xml · derivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500

Underlying: Common Stock, par value $0.0001 per share · 1,500 shares

Expires 2032-04-05

F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following April 5, 2022.

SEC source: 0001104659-22-043277 · tm2212026-4_4seq1.xml · derivative · entry 1

Singer William S. · CIK 0001617927 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500

Underlying: Common Stock, par value $0.0001 per share · 1,500 shares

Expires 2032-04-05

F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following April 5, 2022.

SEC source: 0001104659-22-043271 · tm2212026-1_4seq1.xml · derivative · entry 1

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500

Underlying: Common Stock, par value $0.0001 per share · 1,500 shares

Expires 2032-04-05

F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following April 5, 2022.

SEC source: 0001104659-22-043273 · tm2212026-2_4seq1.xml · derivative · entry 1

SCHECHTER JONATHAN · CIK 0001619259 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500

Underlying: Common Stock, par value $0.0001 per share · 1,500 shares

Expires 2032-04-05

F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following April 5, 2022.

SEC source: 0001104659-22-073972 · tm2219110-3_4aseq1.xml · derivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, par value $0.0001 per share · Not disclosed shares

Expires not disclosed

F1 · security: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.exercise_price: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · kind: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · shares: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · price: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.exercise_date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.expiration_date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.underlying: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.underlying_shares: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · balance_after: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · ownership.direct: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

SEC source: 0001104659-22-073973 · tm2219110-4_4aseq1.xml · derivative · entry 1

Singer William S. · CIK 0001617927 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, par value $0.0001 per share · Not disclosed shares

Expires not disclosed

F1 · security: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.exercise_price: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · kind: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · shares: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · price: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.exercise_date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.expiration_date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.underlying: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.underlying_shares: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · balance_after: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · ownership.direct: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

SEC source: 0001104659-22-073971 · tm2219110-2_4aseq1.xml · derivative · entry 1

SCHECHTER JONATHAN · CIK 0001619259 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, par value $0.0001 per share · Not disclosed shares

Expires not disclosed

F1 · security: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.exercise_price: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · kind: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · shares: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · price: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.exercise_date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.expiration_date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.underlying: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.underlying_shares: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · balance_after: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · ownership.direct: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

SEC source: 0001104659-22-073970 · tm2219110-1_4aseq1.xml · derivative · entry 1

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, par value $0.0001 per share · Not disclosed shares

Expires not disclosed

F1 · security: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.exercise_price: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · kind: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · shares: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · price: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.exercise_date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.expiration_date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.underlying: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · derivative.underlying_shares: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · balance_after: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

F1 · ownership.direct: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio.

SEC source: 0001104659-22-025704 · tm227375-1_4seq1.xml · derivative · entry 1

TUCHMAN ALAN J · CIK 0001417631 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,150

Underlying: Common Stock · 6,150 shares

Expires 2032-02-16

F1 · derivative.exercise_date: This option was issued on February 16, 2022 (the "Grant Date") under the Issuer's 2020 Equity Incentive Plan and will vest in equal quarterly installments over the four quarters following the Grant Date.

SEC source: 0001104659-21-092719 · tm2122331-6_4seq1.xml · nonDerivative · entry 1

Perry George · CIK 0001725758 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

F1 · balance_after: Includes 40,000 restricted stock units granted on July 13, 2021 (the "Grant Date") under the Issuer's 2020 Equity Incentive Plan which will vest 50% on the six month anniversary of the Grant Date and the remaining 50% on the one year anniversary of the Grant Date.

SEC source: 0001104659-21-092713 · tm2122331-2_4seq1.xml · nonDerivative · entry 1

Alkon Daniel L. · CIK 0001686138 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,484

F1 · balance_after: Includes 80,000 restricted stock units granted on July 13, 2021 (the "Grant Date") under the Issuer's 2020 Equity Incentive Plan which will vest 50% on the six month anniversary of the Grant Date and the remaining 50% on the one year anniversary of the Grant Date.

SEC source: 0001104659-21-092722 · tm2122331-8_4seq1.xml · nonDerivative · entry 1

TUCHMAN ALAN J · CIK 0001417631 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

F1 · balance_after: Includes 60,000 restricted stock units granted on July 13, 2021 (the "Grant Date") under the Issuer's 2020 Equity Incentive Plan which will vest 50% on the six month anniversary of the Grant Date and the remaining 50% on the one year anniversary of the Grant Date.

SEC source: 0001104659-21-092716 · tm2122331-4_4seq1.xml · nonDerivative · entry 1

WEINSTEIN ROBERT · CIK 0001213709 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,198

F1 · balance_after: Includes 60,000 restricted stock units granted on July 13, 2021 (the "Grant Date") under the Issuer's 2020 Equity Incentive Plan which will vest 50% on the six month anniversary of the Grant Date and the remaining 50% on the one year anniversary of the Grant Date.

SEC source: 0001104659-21-092712 · tm2122331-1_4seq1.xml · nonDerivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,000

F1 · balance_after: Includes 90,000 restricted stock units granted on July 13, 2021 (the "Grant Date") under the Issuer's 2020 Equity Incentive Plan which will vest 50% on the six month anniversary of the Grant Date and the remaining 50% on the one year anniversary of the Grant Date.

SEC source: 0001104659-21-092721 · tm2122331-7_4seq1.xml · nonDerivative · entry 1

Singer William S. · CIK 0001617927 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

F1 · balance_after: Includes 60,000 restricted stock units granted on July 13, 2021 (the "Grant Date") under the Issuer's 2020 Equity Incentive Plan which will vest 50% on the six month anniversary of the Grant Date and the remaining 50% on the one year anniversary of the Grant Date.

SEC source: 0001104659-21-092718 · tm2122331-5_4seq1.xml · nonDerivative · entry 1

SCHECHTER JONATHAN · CIK 0001619259 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,750

F1 · balance_after: Includes 45,000 restricted stock units granted on July 13, 2021 (the "Grant Date") under the Issuer's 2020 Equity Incentive Plan which will vest 50% on the six month anniversary of the Grant Date and the remaining 50% on the one year anniversary of the Grant Date.

SEC source: 0001104659-21-092715 · tm2122331-3_4seq1.xml · nonDerivative · entry 1

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,078

F1 · balance_after: Includes 50,000 restricted stock units granted on July 13, 2021 (the "Grant Date") under the Issuer's 2020 Equity Incentive Plan which will vest 50% on the six month anniversary of the Grant Date and the remaining 50% on the one year anniversary of the Grant Date.

SEC source: 0001104659-22-123807 · tm2231816-7_4aseq1.xml · nonDerivative · entry 1

Alkon Daniel L. · CIK 0001686138 · Director · President and CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,234

F1 · shares: This filing amends the Form 4, filed on July 15, 2021 by Mr. Alkon to reflect the lower number of options allowed to be granted pursuant to the per-participant grant limit contained in the Issuer's 2020 Equity Incentive Plan, as amended.

SEC source: 0001104659-22-123805 · tm2231816-6_4aseq1.xml · nonDerivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,250

F1 · shares: This filing amends the Form 4, filed on July 15, 2021 by Mr. Silverman to reflect the lower number of options allowed to be granted pursuant to the per-participant grant limit contained in the Issuer's 2020 Equity Incentive Plan, as amended.

SEC source: 0001104659-21-081898 · tm2119874d2_4.xml · nonDerivative · entry 1

Alkon Daniel L. · CIK 0001686138 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,484

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.19 to $8.35, inclusive. The reporting person undertakes to provide to Synaptogenix, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

SEC source: 0001104659-21-081897 · tm2119874d1_4.xml · nonDerivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.75 to $8.49, inclusive. The reporting person undertakes to provide to Synaptogenix, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.